Oncogenes as novel targets for cancer therapy (part III): transcription factors
- PMID: 16196502
- DOI: 10.2165/00129785-200505050-00005
Oncogenes as novel targets for cancer therapy (part III): transcription factors
Abstract
This is the third paper in a four-part serial review on potential therapeutic targeting of oncogenes. The previous parts described the involvement of oncogenes in different aspects of cancer growth and development, and considered the new technologies responsible for the advancement of oncogene identification, target validation, and drug design. Because of such advances, new specific and more efficient therapeutic agents can be developed for cancer. This part of the review continues the exploration of various oncogenes that we have grouped within seven categories: growth factors, tyrosine kinases, intermediate signaling molecules, transcription factors, cell cycle regulators, DNA damage repair genes, and genes involved in apoptosis. Part one discussed growth factors and tyrosine kinases and part two discussed intermediate signaling molecules. This portion of the review covers transcription factors and the various strategies being used to inhibit their expression or decrease their activities.
Similar articles
-
Oncogenes as novel targets for cancer therapy (part II): Intermediate signaling molecules.Am J Pharmacogenomics. 2005;5(4):247-57. doi: 10.2165/00129785-200505040-00005. Am J Pharmacogenomics. 2005. PMID: 16078861 Review.
-
Oncogenes as novel targets for cancer therapy (part IV): regulators of the cell cycle and apoptosis.Am J Pharmacogenomics. 2005;5(6):397-407. doi: 10.2165/00129785-200505060-00006. Am J Pharmacogenomics. 2005. PMID: 16336004 Review.
-
Oncogenes as novel targets for cancer therapy (part I): growth factors and protein tyrosine kinases.Am J Pharmacogenomics. 2005;5(3):173-90. doi: 10.2165/00129785-200505030-00004. Am J Pharmacogenomics. 2005. PMID: 15952871 Review.
-
Transcription factors as drug targets in cancer.Eur J Cancer. 1996 Oct;32A(11):1857-63. doi: 10.1016/0959-8049(96)00214-6. Eur J Cancer. 1996. PMID: 8943667 Review.
-
A stochastic model of oncogene expression and the relevance of this model to cancer therapy.Theor Biol Med Model. 2006 Jan 31;3:5. doi: 10.1186/1742-4682-3-5. Theor Biol Med Model. 2006. PMID: 16448558 Free PMC article.
Cited by
-
The MDM2-p53 pathway revisited.J Biomed Res. 2013 Jul;27(4):254-71. doi: 10.7555/JBR.27.20130030. Epub 2013 Jun 6. J Biomed Res. 2013. PMID: 23885265 Free PMC article.
-
Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression.Hum Pathol. 2007 Nov;38(11):1628-38. doi: 10.1016/j.humpath.2007.03.010. Epub 2007 May 22. Hum Pathol. 2007. PMID: 17521701 Free PMC article.
-
Recent advances in validating MDM2 as a cancer target.Anticancer Agents Med Chem. 2009 Oct;9(8):882-903. doi: 10.2174/187152009789124628. Anticancer Agents Med Chem. 2009. PMID: 19538162 Free PMC article. Review.
-
Use of recombinant cell-permeable small peptides to modulate glucocorticoid sensitivity of acute lymphoblastic leukemia cells.Biochemistry. 2010 Oct 19;49(41):8892-901. doi: 10.1021/bi1007723. Biochemistry. 2010. PMID: 20831260 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources